araag2/HINT huggingface dataset:
Clinical trial NCT00110461 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: aripiprazole, aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Child and adolescent patients with bipolar I disorder, manic or mixed episode with or
             without psychotic features

        Exclusion Criteria:

          -  Patients with certain other psychological disorders

          -  Patients with a co-morbid serious, uncontrolled systemic illness

          -  Patients with significant risk of committing suicide
Clinical trial NCT00736957 (phase 3, status: completed)
Conditions: chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: tramadol hydrochloride (hcl) plus acetaminophen (jns013)
SMILES: COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Participants whose pain cannot be controlled sufficiently with at least 14-day
             continuous treatment with identical oral non steroid anti inflammatory drugs (NSAIDs)
             at a usual maximum dose during 3 months prior to this study

          -  Ambulatory participants without need for any supportive device or assistance during
             daily life

          -  Outpatients

          -  Participants who do not plan to change the therapeutic policy and content of the
             medications for underlying disease during screening period to the end of Treatment
             Period I

          -  Sustention of chronic pain due to Osteo Arthritis (OA), Low Back Pain (LBP),
             Rheumatoid Arthritis (RA), Neck Shoulder Arm Syndrome (NSAS), Diabetic Neuropathy
             (DN), Post herpetic Neuralgia (PHN) or other for at least 3 months

        Exclusion Criteria:

          -  Participants with conditions for which opioids are contraindicated

          -  Participants with conditions for which APAP are contraindicated

          -  Participants with history of convulsion or the possibility of convulsive seizure

          -  Participants with concurrent, previous, or possible alcohol dependence, drug
             dependence, or narcotic addiction

          -  Pregnant Participants or those who may be pregnant, lactating mothers, and
             Participants who wish pregnancy during the study period.
Clinical trial NCT00551135 (phase 3, status: completed)
Conditions: pain, postoperative, hernia, inguinal
ICD codes: K40.11, K40.41, K40.01, K40.21, K40.31, K40.91, K40.10
Drugs: pregabalin, placebo, pregabalin, pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  The subject will have elective ( the subject chooses, but does not have to undergo
             surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using
             mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or
             sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local
             anesthetic infiltration at the conclusion of surgery. Study surgery should be
             anticipated to be in the morning.

          -  Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as
             naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after
             surgery.

          -  The subject will be available for a visit within 72 hours of the day of surgery if not
             admitted the night before for baseline assessments before taking any study medication,
             and then to receive study medication prior to the day before surgery.

          -  The subject is expected and agrees to remain at the hospital (or intermediate care
             facility) for a minimum of 3 hours following surgery.

        Exclusion Criteria:

          -  Subjects with non elective or emergency surgery (must have the surgery no matter
             what), or hernia with incarceration (the trapping of abdominal contents within the
             hernia itself).

          -  Subjects with hernia repair that is not a primary repair. The planned use of nerve
             block or spinal/epidural/paravertebral anesthesia or surgery is not planned with
             general anesthesia.

          -  Subjects that are not allowed to receive the anesthesia agents indicated per protocol
             and general anesthesia.
Clinical trial NCT00419952 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol (symbicort) pmdi, budesonide hfa pmdi
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female, African American (self-reported), ≥12 years of age

          -  Moderate to severe asthma requiring treatment with an inhaled corticosteroid

          -  Diagnosis of asthma for at least 6 months

        Exclusion Criteria:

          -  Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral,
             ocular)

          -  Any significant disease or disorder that may jeopardize a subject's safety
Clinical trial NCT00395135 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: lorcaserin 10 mg bid, matching placebo bid
SMILES: C[C@H]1CNCCC2=CC=C(Cl)C=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9
             kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia,
             cardiovascular disease, glucose intolerance, sleep apnea)

          -  Ability to complete a 2 year study

        Exclusion Criteria:

          -  Diabetes

          -  Pregnancy

          -  History of heart valve disease

          -  Serious or unstable current or past medical conditions
Clinical trial NCT01186744 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cp-690,550, cp-690,550, cp-690,550, cp-690,550
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at
             least 12 months prior to first dose of study drug;

          -  Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's
             Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at
             least 10% of body surface area;

          -  No evidence of active or latent or inadequately treated infection with Tuberculosis or
             other serious infections.

        Exclusion Criteria:

          -  Non-plaque or drug induced forms of psoriasis;

          -  Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot
             discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B).

          -  Any uncontrolled significant medical condition.
Clinical trial NCT00578305 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, methylprednisolone, methotrexate, folic acid or folate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, 18-80 years of age.

          -  Active rheumatoid arthritis for ≥ 3 months and ≤ 10 years.

          -  Evidence of erosive disease and/or clinical synovitis in a signal joint.

          -  Inadequate response to 12.5-25 mg/week methotrexate for ≥ 12 weeks.

        Exclusion Criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid
             arthritis. - Any surgical procedure within 12 weeks prior to baseline.

          -  Previous treatment with a biologic agent or with a B cell modulating or cell depleting
             therapy.
Clinical trial NCT00473460 (phase 3, status: completed)
Conditions: lung diseases, bronchitis, chronic
ICD codes: J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122
Drugs: avelox (moxifloxacin, bay12-8039), placebo
SMILES: [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female out-patients >/= 45 years

          -  Subjects suffering from chronic bronchitis

          -  FEV1</= 70% and FEV1/FVC </= 70% predicted from age, height and sex

          -  No documented episode of AECB (requiring treatment) within 6 weeks of randomization
             and not experiencing an exacerbation at the time of screening

          -  Sputum production on most days, even when exacerbation free

          -  Subjects presented with at least two documented (i.e. requiring antibiotics and/or
             systemic steroid administration) acute exacerbation episodes during the last 12
             monthsIf receiving chronic therapy with inhaled long acting bronchodilators and/or
             inhaled or systemic steroids, the treatment must have remained stable for the
             preceding 6 weeks prior to screening

          -  Smoking history of at least 20 pack-years

          -  Subjects willing and able to give fully informed written consent

        Exclusion Criteria:

          -  Subjects with contra-indications to moxifloxacin- Known bronchial carcinoma, pulmonary
             tuberculosis, cystic fibrosis, documented chronic bronchial asthma or diffuse
             bronchiectasis- Subjects who are actively participating in intensive pulmonary
             rehabilitation programs

          -  Subjects with a known history of chronic colonization of pathogenic organisms
             resistant to moxifloxacin, e.g. Pseudomonas spp, MRSA

          -  No systemic or inhaled antibiotic therapy during the 6 weeks prior to screening and
             any long term antibiotic usage

          -  Subjects requiring home ventilatory support for COPD and those who have a tracheostomy
             in situ (subjects requiring home/potable oxygen therapy or CPAP for sleep apnea can be
             included)
Clinical trial NCT00132717 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: mk0653a (ezetimibe [+] simvastatin), comparator: atorvastatin, comparator: fluvastatin, comparator: lovastatin, comparator: pravastatin, comparator: rosuvastatin, comparator: simvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC, [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients greater than 18 years old, who were admitted to a hospital for an
             investigation of a heart problem and are currently receiving an approved medication to
             lower cholesterol

        Exclusion Criteria:

          -  Patients who have congestive heart failure (CHF), uncontrolled high blood pressure,
             poorly controlled blood sugar, impaired kidney function, or HIV.
Clinical trial NCT00246220 (phase 3, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hydrochloride
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with a diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD) according
             to DSM-IV criteria

          -  ADHD symptoms from childhood to adulthood, with some symptoms present before age 7
             years which continue to meet DSM-IV criteria at the time of assessment. (ADHD is not
             diagnosed if the symptoms are better accounted for by another psychiatric disorder.)

        Exclusion Criteria:

          -  Patients known to be a non-responder to methylphenidate or known to have a child who
             is a non-responder to methylphenidate

          -  treated with any methylphenidate-containing medication within 1 month of starting the
             study

          -  have any clinically unstable psychiatric condition including, but not limited to the
             following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder,
             anti-social personality disorder, borderline personality disorder

          -  family history of schizophrenia or affective psychosis

          -  patients with motor tics or a history of Tourette's syndrome, or with a substance
             abuse or dependence disorder, an eating disorder, or mental retardation

          -  using any medications which may affect the evaluation of study results
Clinical trial NCT00558259 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran etexilate 150 mg twice daily (bid), matching placebo twice daily (bid)
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been
             treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an
             oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER
             study medication up to the moment of screening for the current study.

          2. Written informed consent

        Exclusion criteria:

          1. Younger then 18 years of age

          2. Indication for VKA other than DVT and/or PE

          3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued

          4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis,
             chronic active hepatitis, cirrhosis) or ALAT > 3 x ULN

          5. Creatinine clearance < 30 ml/min

          6. Acute bacterial endocarditis

          7. Active bleeding or high risk for bleeding.

          8. Uncontrolled hypertension (investigators judgement)

          9. Intake of another experimental drug within the 30 days prior to randomization into the
             study

         10. Life expectancy <6 months

         11. Childbearing potential without proper contraceptive measures*, pregnancy or breast
             feeding
Clinical trial NCT00137995 (phase 3, status: completed)
Conditions: lymphoma, large-cell, diffuse
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, etoposide, carboplatine, ifosfamide + mesna, cisplatine, cytosine arabinoside, dexamethasone, bcnu, etoposide, cytarabine, melphalan
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], OS(=O)(=O)CCS, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with CD20-positive diffuse large B-cell lymphoma. Disease must be
             histologically proven in case of relapse or partial response.

          -  Aged 18 to 65 years

          -  First relapse after complete remission (CR), less than partial remission (PR) or
             partial response to first line treatment not achieving documented or confirmed
             complete remission.

          -  Eligible for transplant

          -  Previously treated with chemotherapy regimen containing anthracyclines with or without
             rituximab.

          -  ECOG performance status 0 to 2.

          -  Minimum life expectancy of 3 months.

          -  Signed written informed consent prior to randomization.

        Exclusion Criteria:

          -  Burkitt, mantle-cell and T-cell lymphoma.

          -  CD20-negative diffuse large cell lymphoma

          -  Documented infection with HIV and hepatitis B virus [HBV] (in the absence of
             vaccination)

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Not previously treated with anthracycline-containing regimens

          -  Prior transplantation

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Any serious active disease or co-morbid condition (according to the investigator's
             decision and information provided in the Investigational Drug Brochure [IDB]).

          -  Poor renal function (creatinine level > 150µmol/l or 1.5-2.0 x upper limit of normal
             [ULN]); poor hepatic function (total bilirubin level > 30mmol/l [> 1.5 x ULN],
             transaminases > 2.5 maximum normal level) unless these abnormalities are related to
             the lymphoma; poor bone marrow reserve as defined by neutrophils < 1.5G/l or platelets
             < 100G/l, unless related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Pregnant women

          -  Adult patients unable to provide informed consent because of intellectual impairment.
Clinical trial NCT00415142 (phase 3, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: saredutant (sr48968), placebo, escitalopram
SMILES: CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of major depressive disorder, recurrent, as defined by Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR)
             criteria (296.3) and confirmed by the semi-structured Mini International
             Neuropsychiatric Interview (MINI).

        Exclusion Criteria:

          -  Total score of less than 23 on the MADRS.

          -  HAM-D total score less than 17.

          -  Duration of the current depressive episode less than 1 month or greater than 2 years.

          -  Patients with an Mini Mental State Examination score of less than 23.

          -  Patients with a history or presence of bipolar disorders or psychotic disorders.

          -  Patients with alcohol/substance dependence or abuse in the past 12 months except
             nicotine or caffeine dependence.

          -  Patients who have used the following prior to entry into Acute Phase: antipsychotics
             within 3 months, fluoxetine within 1 month, monoamine oxidase inhibitors within 4
             weeks, other antidepressants, or mood-stabilizer (lithium, anticonvulsants) within 1
             week.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate
Clinical trial NCT00489736 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: dronedarone (sr33589), amiodarone
SMILES: CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented atrial fibrillation for more than 72 hours for whom
             cardioversion and antiarrhythmic treatment is indicated in the opinion of the
             investigator and under oral anticoagulation

        Exclusion Criteria:

          -  Contraindication to oral anticoagulation

          -  Patient having received amiodarone in the past whatever the date (more than a total of
             twenty 200 mg tablets or more than 5 days intravenous)

          -  Patients known to have chronic AF, patients with atrial flutter or paroxysmal atrial
             fibrillation

          -  Severe congestive heart failure with New-York Heart Association (NYHA) class III or
             IV, severe bradycardia, high degree atrio-ventricular block, ongoing potentially
             dangerous symptoms when in AF such as angina pectoris, transient ischemic attacks,
             stroke, syncope, as judged by the investigator, first degree family history of sudden
             cardiac death below age 50 years in the absence of coronary heart disease, significant
             sinus node disease without a permanent pacemaker implanted

          -  History of torsades de pointes or long QT syndrome or QT- or QTc-interval ≥500 msecs
             before randomization

          -  Treatment with other class I or III antiarrhythmic drugs which cannot be discontinued

          -  Dysthyroidism or other contraindication to amiodarone

        The above information are not intended to contain all the considerations relevant to a
        patient's potential participation in a clinical trial.